Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of “Buy” from Analysts

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) has been assigned a consensus rating of “Buy” from the fourteen analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $184.78.

Several research firms have recently weighed in on ASND. Morgan Stanley raised their price target on shares of Ascendis Pharma A/S from $180.00 to $197.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 15th. Citigroup initiated coverage on shares of Ascendis Pharma A/S in a research note on Monday, February 28th. They issued a “buy” rating and a $187.00 price target on the stock. SVB Leerink lifted their target price on shares of Ascendis Pharma A/S from $190.00 to $193.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 15th. Wedbush reaffirmed an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Monday, March 28th. Finally, Zacks Investment Research cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Monday, January 17th.

Several hedge funds have recently made changes to their positions in ASND. Bank Julius Baer & Co. Ltd Zurich grew its holdings in Ascendis Pharma A/S by 51.2% during the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 195 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 66 shares in the last quarter. Atria Investments LLC grew its holdings in Ascendis Pharma A/S by 0.9% during the 4th quarter. Atria Investments LLC now owns 9,576 shares of the biotechnology company’s stock worth $1,288,000 after acquiring an additional 88 shares in the last quarter. OneAscent Financial Services LLC grew its holdings in Ascendis Pharma A/S by 3.2% during the 4th quarter. OneAscent Financial Services LLC now owns 3,560 shares of the biotechnology company’s stock worth $479,000 after acquiring an additional 109 shares in the last quarter. Profund Advisors LLC grew its holdings in Ascendis Pharma A/S by 4.4% during the 3rd quarter. Profund Advisors LLC now owns 3,124 shares of the biotechnology company’s stock worth $498,000 after acquiring an additional 133 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in Ascendis Pharma A/S by 17.8% during the 1st quarter. SG Americas Securities LLC now owns 942 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 142 shares in the last quarter.

ASND stock traded up $4.72 during midday trading on Tuesday, hitting $83.62. 4,667 shares of the stock traded hands, compared to its average volume of 426,407. The firm has a market cap of $4.76 billion, a P/E ratio of -10.12 and a beta of 0.86. The stock’s fifty day simple moving average is $107.88 and its 200-day simple moving average is $124.02. Ascendis Pharma A/S has a 1-year low of $75.70 and a 1-year high of $178.71.

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) last announced its earnings results on Wednesday, March 2nd. The biotechnology company reported ($2.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.57) by $0.43. The business had revenue of $5.60 million for the quarter, compared to analyst estimates of $2.78 million. Ascendis Pharma A/S had a negative net margin of 5,015.63% and a negative return on equity of 45.19%. Sell-side analysts anticipate that Ascendis Pharma A/S will post -8.95 EPS for the current year.

About Ascendis Pharma A/S (Get Rating)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

Recommended Stories

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.